Meikang Biotech: Announcement of Supervisory Board Resolution
Meikang Biotechnology Co., Ltd. Securities code: 300439 Securities abbreviation: Meikang Biotechnology Announcement number: 2025-047
Meikang Biotechnology Co., Ltd.
Announcement of Resolutions of the 14th Meeting of the Fifth Supervisory Board
The Company and all members of the Supervisory Board guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
The 14th meeting of the fifth supervisory board of Meikang Biotechnology Co., Ltd. (hereinafter referred to as the "Company") was held on August 28, 2025 in the company's conference room through on-site communication and communication. The meeting notice was sent to all supervisors by phone, email, etc. on August 18, 2025. 3 supervisors should be present at the meeting, and 3 supervisors were actually present. The meeting was convened and chaired by Ms. Tian Xiaoyan, chairman of the supervisory board. The convening and holding of this meeting complied with the relevant provisions of the "Company Law of the People's Republic of China" and the Articles of Association of Meikang Biotechnology Co., Ltd. (hereinafter referred to as the "Articles of Association"), and is legal and valid.
After deliberation and voting by the supervisors present at the meeting, the following proposals were adopted:
- Review and unanimously adopt the "Proposal on the Company's 2025 Semi-Annual Report and its Summary"
The company has prepared the "Full Text of the 2025 Semi-Annual Report" and the "Summary of the 2025 Semi-Annual Report". After deliberation, the Board of Supervisors believes that: the preparation and review procedures of the company's above-mentioned report comply with the provisions of laws, administrative regulations and the Articles of Association, and its content and format comply with various regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange. The information contained truly, accurately and completely reflects the company's financial status, operating results and other actual conditions for the first half of 2025, and there are no false records, misleading statements or major omissions.
For details, please refer to the relevant announcement published on the GEM information disclosure website designated by the China Securities Regulatory Commission on the same day.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions. Agreeing votes account for 100% of the valid voting rights.
- Review and unanimously adopt the "Proposal on the Special Report on the Deposit and Use of Funds Raised in the Half-Year of 2025"
After a comprehensive review of the progress of investment projects with raised funds during the reporting period, the Board of Supervisors believes that:
1/3
The storage, use, management and disclosure of funds raised by Meikang Biotechnology Co., Ltd. are strictly in accordance with the provisions and requirements of relevant laws, regulations and normative documents, and there are no violations. The content of the "Special Report on the Storage and Use of Raised Funds for the Half Year of 2025" prepared by the company's board of directors truly, accurately and completely reflects the actual situation of the company's storage and use of raised funds for the half year of 2025.
For details, please refer to the relevant announcement published on the GEM information disclosure website designated by the China Securities Regulatory Commission on the same day.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions. Agreeing votes account for 100% of the valid voting rights.
- Reviewed and unanimously approved the "Proposal on Increasing the Estimated Daily Related Transactions in 2025"
After review, the Board of Supervisors believes that the increase in expected daily related transactions in 2025 is in line with the actual situation of the company's business development. The related transactions between the company and related parties are required for the company's normal and necessary business operations and are conducted on the basis of fairness and reasonableness and consensus between both parties. The prices of these related-party transactions are based on fair market prices, are clearly and reasonably priced, and comply with the principles of fairness, fairness and impartiality. There is no harm to the interests of the company and its shareholders, especially small and medium-sized shareholders; it will not affect the company's independence, nor will it affect the company's ability to continue operating. The decision-making process and content of this matter comply with the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies", "Company Articles", "Related Transaction Management Measures" and other legal and regulatory requirements. Therefore, the Board of Supervisors agreed that the company would increase its daily related-party transaction estimates for 2025.
For details, please refer to the relevant announcement published on the GEM information disclosure website designated by the China Securities Regulatory Commission on the same day.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions. Agreeing votes account for 100% of the valid voting rights.
4. Reviewed and unanimously approved the "Proposal on Using Idle Own Funds for Entrusted Financial Management"
After deliberation, the Board of Supervisors believes that: on the premise of ensuring daily operating capital needs and capital security, the total amount used by the company shall not exceed RMB 60,000. Ten thousand yuan of idle self-owned funds are used to purchase cash management products or wealth management products with high security, good liquidity and controllable risks, which can improve the efficiency and income of the company's capital use and obtain more investment returns for the company and shareholders; it will not affect the normal development of the company's main business and will not harm the interests of the company and shareholders, especially small and medium-sized shareholders; the decision-making and review procedures for matters comply with the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the "Shenzhen Stock Exchange Listed Companies Self-Discipline Supervision Guidelines"
2/3
Meikang Biotechnology Co., Ltd. No. 2 - Standardized Operation of GEM Listed Companies, "Articles of Association" and other relevant laws, regulations and normative documents. Therefore, the Board of Supervisors agreed that the company would use its idle own funds for entrusted financial management.
For details, please refer to the relevant announcement published on the GEM information disclosure website designated by the China Securities Regulatory Commission on the same day.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions. Agreeing votes account for 100% of the valid voting rights.
5. Documents for reference
Resolution of the 14th meeting of the fifth board of supervisors;
Other documents required by Shenzhen Stock Exchange.
Announcement is hereby made.
Meikang Biotechnology Co., Ltd. Supervisory Board August 29, 2025
3/3